HOLY CROSS HOSPITAL
- Type
- Teaching hospital
- Where
- Silver Spring, MD
- Medicare CCN
- 210004
- Received
- $1,449,895 in 55 records, 2020 ($4,712 general, $1,445,182 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: HOLY CROSS HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: HOLY CROSS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 14 | $4,712 |
| 2020 | Research payment | 41 | $1,445,182 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Gilead Sciences, Inc. | 14 | $1,202,419 | 2020 |
| AstraZeneca Pharmaceuticals LP | 9 | $66,709 | 2020 |
| Novartis Pharmaceuticals Corporation | 1 | $62,371 | 2020 |
| Genentech, Inc. | 7 | $51,349 | 2020 |
| GlaxoSmithKline, LLC. | 1 | $27,650 | 2020 |
| Medtronic, Inc. | 8 | $19,138 | 2020 |
| PFIZER INC. | 1 | $15,544 | 2020 |
| Stryker Corporation | 9 | $3,388 | 2020 |
| Aesculap, Inc. | 3 | $885 | 2020 |
| Zimmer Biomet Holdings, Inc. | 1 | $239 | 2020 |
| Hikma Pharmaceuticals USA | 1 | $199 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 41 | $1,445,182 |
| Gift | 13 | $4,513 |
| Food and Beverage | 1 | $199 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $2,235 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenanc | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $2,083 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-12-31 | Stryker Corporation | $1,023 | Gift | In-kind items and services | S3 Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,023 | Gift | In-kind items and services | S3 Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | Stryker Corporation | $974 | Gift | In-kind items and services | S3 Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $239 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $0 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2020 |
| 2020-12-15 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-12-10 | Aesculap, Inc. | $402 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $276 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $206 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-11-24 | Genentech, Inc. | $6,500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-11-23 | GlaxoSmithKline, LLC. | $27,650 | Research payment | Cash or cash equivalent | A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA | 2020 | |
| 2020-11-19 | Medtronic, Inc. | $3,230 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2020 |
| 2020-11-19 | Medtronic, Inc. | $876 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2020 |
| 2020-11-16 | Gilead Sciences, Inc. | $1,627 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-11-10 | Genentech, Inc. | $33,062 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-11-10 | Genentech, Inc. | $6,309 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-11-10 | Genentech, Inc. | $3,057 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-11-10 | Genentech, Inc. | $1,170 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-10-29 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2020 |
| 2020-10-06 | AstraZeneca Pharmaceuticals LP | $16,500 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Bes | 2020 |
| 2020-09-14 | Gilead Sciences, Inc. | $2,000 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-08-31 | Medtronic, Inc. | $3,441 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2020 |
| 2020-08-31 | Medtronic, Inc. | $2,128 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2020 |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-31 | Stryker Corporation | $61 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2020 | |
| 2020-08-19 | Gilead Sciences, Inc. | $3,410 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-08-10 | Hikma Pharmaceuticals USA | $199 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-07-22 | Gilead Sciences, Inc. | $16,101 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-20 | Gilead Sciences, Inc. | $1,627 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $568,373 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $430 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-15 | Gilead Sciences, Inc. | $9,421 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-10 | Gilead Sciences, Inc. | $11,280 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-21 | Medtronic, Inc. | $3,477 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2020 |
| 2020-05-21 | Medtronic, Inc. | $1,314 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $548,437 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $9,119 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-11 | Gilead Sciences, Inc. | $2,500 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-04 | Gilead Sciences, Inc. | $14,047 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-04 | Gilead Sciences, Inc. | $14,047 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-04-03 | AstraZeneca Pharmaceuticals LP | $921 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2020 |
| 2020-03-12 | AstraZeneca Pharmaceuticals LP | $2,750 | Research payment | Cash or cash equivalent | TAGRISSO Drug, Oncology | A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenanc | 2020 |
| 2020-03-05 | AstraZeneca Pharmaceuticals LP | $13,950 | Research payment | Cash or cash equivalent | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo | 2020 | |
| 2020-02-27 | Medtronic, Inc. | $3,704 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2020 |
| 2020-02-27 | Medtronic, Inc. | $964 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2020 |
| 2020-02-25 | AstraZeneca Pharmaceuticals LP | $14,405 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2020 |
| 2020-02-18 | Novartis Pharmaceuticals Corporation | $62,371 | Research payment | Cash or cash equivalent | PIQRAY Drug, ONCOLOGY | A PHASE II MULTICENTER OPEN LABEL TWO COHORT NON COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS F | 2020 |
| 2020-01-28 | PFIZER INC. | $15,544 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2020 |
| 2020-01-16 | AstraZeneca Pharmaceuticals LP | $13,863 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Silver Spring, MD, county Montgomery County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Silver Spring, MD | County Montgomery County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 81,462 | 1,065,949 | 6,206,011 |
| Population, 2020 census P1 | 81,015 | 1,062,061 | 6,177,224 |
| Median age B01002 | 35.6 | 40.2 | 39.4 |
| Under 18 B01001 | 22.2% | 22.8% | 22.2% |
| 65 and over B01001 | 12.1% | 17.0% | 16.7% |
| Households B11001 | 33,988 | 389,210 | 2,362,928 |
| Foreign born B05002 | 33.9% | 33.6% | 16.6% |
| Median household income B19013 | $99,860 | $132,450 | $103,678 |
| Median family income B19113 | $126,101 | $164,096 | $127,817 |
| Per capita income B19301 | $57,635 | $67,571 | $52,979 |
| Poverty rate B17001 | 10.6% | 7.5% | 9.4% |
| Unemployment rate B23025 | 5.4% | 4.9% | 4.9% |
| Civilian labor force B23025 | 50,814 | 590,776 | 3,313,651 |
| Mean commute (minutes) B08013 | 34.0 | 31.9 | 31.1 |
| Bachelor's degree or higher B15003 | 60.6% | 60.6% | 43.4% |
| Housing units B25001 | 35,774 | 406,531 | 2,560,784 |
| Owner-occupied B25003 | 38.3% | 65.3% | 67.6% |
| Renters B25003 | 61.7% | 34.7% | 32.4% |
| Median home value B25077 | $643,300 | $640,300 | $419,900 |
| Median gross rent B25064 | $1,913 | $2,068 | $1,705 |
| White, not Hispanic B03002 | 32.8% | 39.5% | 46.6% |
| Black B03002 | 28.3% | 18.3% | 28.9% |
| Hispanic or Latino B03002 | 24.5% | 21.0% | 12.5% |
| Asian B03002 | 8.5% | 15.3% | 6.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Silver Spring, MD.
Comments